Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey
2020
Abstrakt
The outcome of patients who received idelalisib before alloSCT was comparable with previous reports of alloSCT in FL patients without idelalisib pretreatment. Idelalisib seems to be an effective and safe drug for bridging patients with FL to alloSCT, especially in the chemotherapy-refractory setting, with a high percentage of patients with responding disease at the time of transplant.
However, further studies are required to confirm that idelalisib bridging does not increase the risk of aGvHD.